These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12381851)

  • 41. Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood.
    Böldicke T; Tesar M; Griesel C; Rohde M; Gröne HJ; Waltenberger J; Kollet O; Lapidot T; Yayon A; Weich H
    Stem Cells; 2001; 19(1):24-36. PubMed ID: 11209088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach.
    Ewert S; Honegger A; Plückthun A
    Biochemistry; 2003 Feb; 42(6):1517-28. PubMed ID: 12578364
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Conserved residues and their role in the structure, function, and stability of acyl-coenzyme A binding protein.
    Kragelund BB; Poulsen K; Andersen KV; Baldursson T; Krøll JB; Neergård TB; Jepsen J; Roepstorff P; Kristiansen K; Poulsen FM; Knudsen J
    Biochemistry; 1999 Feb; 38(8):2386-94. PubMed ID: 10029532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The invariant tryptophan in an H chain V region is not essential to antibody binding.
    Sharon J
    J Immunol; 1988 Apr; 140(8):2666-9. PubMed ID: 3128602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells.
    Hamdy N; Goustin AS; Desaulniers JP; Li M; Chow CS; Al-Katib A
    J Immunol Methods; 2005 Feb; 297(1-2):109-24. PubMed ID: 15777935
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved antigen binding by a CD20-specific single-chain antibody fragment with a mutation in CDRH1.
    Adamson PJ; Millard DJ; Hohmann AW; Mavrangelos C; Macardle PJ; Pilkington G; Mulhern TD; Tedder TF; Zola H; Nicholson IC
    Mol Immunol; 2006 Feb; 43(6):550-8. PubMed ID: 15936081
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering.
    Wörn A; Plückthun A
    Biochemistry; 1999 Jul; 38(27):8739-50. PubMed ID: 10393549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selection for improved protein stability by phage display.
    Jung S; Honegger A; Plückthun A
    J Mol Biol; 1999 Nov; 294(1):163-80. PubMed ID: 10556036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extended half-life upon binding of destabilized intrabodies allows specific detection of antigen in mammalian cells.
    Sibler AP; Courtête J; Muller CD; Zeder-Lutz G; Weiss E
    FEBS J; 2005 Jun; 272(11):2878-91. PubMed ID: 15943819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Engineering scFvs for improved stability.
    Chowdhury PS; Vasmatzis G
    Methods Mol Biol; 2003; 207():237-54. PubMed ID: 12412478
    [No Abstract]   [Full Text] [Related]  

  • 51. Determinants of the assembly and function of antibody variable domains.
    Herold EM; John C; Weber B; Kremser S; Eras J; Berner C; Deubler S; Zacharias M; Buchner J
    Sci Rep; 2017 Sep; 7(1):12276. PubMed ID: 28947772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody Binding Selectivity: Alternative Sets of Antigen Residues Entail High-Affinity Recognition.
    Nominé Y; Choulier L; Travé G; Vernet T; Altschuh D
    PLoS One; 2015; 10(12):e0143374. PubMed ID: 26629896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.
    Alvarenga LM; Zahid M; di Tommaso A; Juste MO; Aubrey N; Billiald P; Muzard J
    Toxins (Basel); 2014 Aug; 6(8):2541-67. PubMed ID: 25153256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of scoring functions for antibody sequence assessment and optimization.
    Seeliger D
    PLoS One; 2013; 8(10):e76909. PubMed ID: 24204701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. On the binding affinity of macromolecular interactions: daring to ask why proteins interact.
    Kastritis PL; Bonvin AM
    J R Soc Interface; 2013 Feb; 10(79):20120835. PubMed ID: 23235262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-function relationships of the antigenicity of mycolic acids in tuberculosis patients.
    Beukes M; Lemmer Y; Deysel M; Al Dulayymi JR; Baird MS; Koza G; Iglesias MM; Rowles RR; Theunissen C; Grooten J; Toschi G; Roberts VV; Pilcher L; Van Wyngaardt S; Mathebula N; Balogun M; Stoltz AC; Verschoor JA
    Chem Phys Lipids; 2010 Nov; 163(8):800-8. PubMed ID: 20875402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.
    Kvam E; Sierks MR; Shoemaker CB; Messer A
    Protein Eng Des Sel; 2010 Jun; 23(6):489-98. PubMed ID: 20378699
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Probing the local conformational change of alpha1-antitrypsin.
    Baek JH; Im H; Kang UB; Seong KM; Lee C; Kim J; Yu MH
    Protein Sci; 2007 Sep; 16(9):1842-50. PubMed ID: 17660256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional aspects of co-variant surface charges in an antibody fragment.
    Hugo N; Lafont V; Beukes M; Altschuh D
    Protein Sci; 2002 Nov; 11(11):2697-705. PubMed ID: 12381851
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
    Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.